Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients

Launched by MANSOURA UNIVERSITY · Apr 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Roxadustat, which is a pill designed to treat anemia (low red blood cell count) in patients with severe kidney failure who require hemodialysis. Researchers are interested in finding out whether Roxadustat can also help with other health issues that these patients often face, such as bone health problems and mental health conditions like depression and anxiety. The study will include 46 patients who are on hemodialysis, and they will be divided into two groups: one group will receive Roxadustat three times a week, while the other group will continue with their usual treatment for anemia.

To be eligible for the study, participants must be over 18 years old, willing to sign consent, and have been on hemodialysis for more than three months. The trial will last for six months, during which participants will undergo regular blood tests, bone scans to check bone density, ultrasounds to assess nerve and muscle health, and complete questionnaires about their mood. This research aims to compare the effects of Roxadustat with standard treatment and gain insights into how it may benefit bone health and mental well-being in patients undergoing hemodialysis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The age of the patient is more than 18.
• • Patients who are willing to sign informed consent.
• • Patients with ESKD on chronic hemodialysis for more than 3 months.
• Exclusion Criteria:
• • Current pregnancy or lactation.
• • Patients with pre-existing malignancy.
• • patients with psychosis.
• • Known history of hematological disorders or other causes of anemia other than CKD.
• • Taking medications that may significantly affect or interact with bone metabolism such as osteo-anabolics or bone resorptives during the last 6 months.